Dose Escalation of SNK-396 in Participants With Elevated Low-Density Lipoprotein Cholesterol

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
This is a Phase 1, multi-center, randomized, double-blinded, placebo-controlled single and multiple dose escalation study with SC doses of SNK-396 in participants with elevated LDL-C. The study will be divided into two parts: * SAD cohorts * MAD cohorts
Epistemonikos ID: 64b7540fa4b1323677f24941dbc93a37b35a0af1
First added on: Feb 19, 2024